X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-20

Reporting Person: Bill & Melinda Gates Foundation (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-20	Common Stock	C	722179	—	Acquired	722179	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-20	Series D Convertible Preferred Stock	$	C	2464799	Disposed		Common Stock (722179)	Direct

Footnotes

F1: Upon closing of the issuer's initial public offering, the Series D Convertible Preferred Stock converted automatically into Common Stock on a 0.29300-for-1 basis without payment of further consideration. There was no expiration date for the Series D Convertible Preferred Stock.